“…Among the treatment modalities that are available for patients with ESRD, KT is preferred because it is associated with an improved life expectancy, better quality of life, and is cost-effective both for patients and for payers (1-4, 7-15, 18-25, 31-42). However, with the increasing disparity between the steadily rising number of potential transplant candidates and relatively static number of available organs, ethical concerns have been expressed that providing elderly patients with ESRD with scarce DD kidneys may result in significant limitations imposed on the useful life of donor organs (3,4,(20)(21)(22)(23)(24)(25)(37)(38)(39)(40)(41). However, a number of studies have demonstrated that KT offers both a cost and survival benefit to virtually all patients with ESRD regardless of age (3,4,7,8,(18)(19)(20)(21)(22)(23)(24)(25)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42).…”